Abstract
To present the chemistry, pharmacology, and pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor (DTI), and to review available comparative clinical trial data evaluating its efficacy and safety relative to other antithrombotic agents in the prevention and treatment of thromboembolism. A search of the PubMed and Cochrane databases (1995-August 2004), supplemented by a manual search of article bibliographies, conference abstracts, and data on file from the manufacturer, was conducted. Key search terms were ximelagatran, melagatran, H376/95, and direct thrombin inhibitors. Pertinent information from available clinical trials, including study design, patient demographics, dosing regimens, anticoagulant comparators, methods for evaluating effectiveness, treatment outcomes, adverse events, and pharmacokinetic and pharmacodynamic evaluations, was extracted. Ximelagatran is an orally administered DTI under development for use in the treatment of venous thromboembolism (VTE), long-term prevention of a second VTE event, stroke secondary to atrial fibrillation, prevention of VTE after orthopedic procedures, and recurrent ischemic events after acute myocardial infarction. Ximelagatran, in twice-daily doses of 24 or 36 mg, i...Continue Reading
References
Jul 27, 1996·Lancet·A PlanesY Huet
Sep 5, 1996·The New England Journal of Medicine·D BergqvistG Nylander
Feb 6, 1997·The New England Journal of Medicine·S SchulmanE Loogna
Jul 29, 1998·Archives of Internal Medicine·R H WhiteW Bargar
Jun 4, 1999·Stroke; a Journal of Cerebral Circulation·R G HartR W Asinger
Jun 12, 1999·Annals of Internal Medicine·M K GouldA M Garber
Sep 28, 1999·Medicine·N LevitanA A Rimm
Nov 30, 1999·Annals of Internal Medicine·R G Hart, J L Halperin
Dec 11, 1999·JAMA : the Journal of the American Medical Association·S S Anand, S Yusuf
Dec 28, 1999·Annals of Internal Medicine·A S GoD E Singer
Apr 13, 2000·Archives of Internal Medicine·G P SamsaJ Bian
Jul 25, 2000·Archives of Internal Medicine·R D HullR Brant
Feb 7, 2001·Chest·J HirshJ E Dalen
Feb 7, 2001·Chest·W H GeertsH B Wheeler
Feb 7, 2001·Chest·T M HyersJ G Weg
Feb 7, 2001·Chest·G W AlbersD E Singer
Feb 24, 2001·Journal of the American College of Cardiology
Mar 3, 2001·Thrombosis Research·M ElgD Gustafsson
Mar 3, 2001·Thrombosis Research·D GustafssonR Bylund
Mar 27, 2001·The Journal of Bone and Joint Surgery. American Volume·P C CompUNKNOWN Enoxaparin Clinical Trial Group
Sep 18, 2001·Clinical Therapeutics·A J ClaxtonC Pierce
Nov 14, 2001·Archives of Internal Medicine·J A HeitUNKNOWN AstraZeneca Arthroplasty Study Group
Oct 17, 2001·Annals of Internal Medicine·T E Warkentin
Feb 6, 2002·Circulation·Louis D FioreUNKNOWN Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group
Mar 26, 2002·Clinical Therapeutics·Michael IskedjianA Lane Ilersich
Apr 10, 2002·Pharmacotherapy·Simon de Denus, Sarah A Spinler
Jul 20, 2002·Lancet·Robert F van EsUNKNOWN Antithrombotics in the Secondary Preventionof Events in Coronary Thrombosis-2 (ASPECT-2) Research Group
Aug 7, 2002·Circulation·Marc A BrouwerFreek W A Verheugt
Sep 27, 2002·The New England Journal of Medicine·Mette HurlenHarald Arnesen
Oct 16, 2002·Annals of Internal Medicine·Charles W FrancisClifford W Colwell
Nov 16, 2002·Lancet·Bengt I ErikssonUNKNOWN Melagatran for Thrombin inhibition in Orthopaedic surgery
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Dec 6, 2002·The New England Journal of Medicine·Isabelle C Van GelderUNKNOWN Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group
Feb 14, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ulf G ErikssonDavid Gustafsson
Feb 26, 2003·The New England Journal of Medicine·Paul M RidkerUNKNOWN PREVENT Investigators
Mar 22, 2003·Clinical Pharmacokinetics·Linda C JohanssonUlf G Eriksson
Mar 28, 2003·American Heart Journal·Ewurabena SimpsonLouise Pilote
Mar 29, 2003·Blood·Jorge NievaAlan Saven
Apr 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bernd Clement, Katrin Lopian
May 13, 2003·Clinical Pharmacokinetics·Linda C JohanssonUlf G Eriksson
May 13, 2003·Clinical Pharmacokinetics·Troy C SarichUlf G Eriksson
May 13, 2003·Expert Opinion on Pharmacotherapy·Karen L Kaplan
May 14, 2003·Journal of the American College of Cardiology·Palle PetersenUNKNOWN SPORTIF II Investigators
May 14, 2003·European Journal of Clinical Pharmacology·Ulf G ErikssonDavid Gustafsson
May 30, 2003·The Annals of Pharmacotherapy·William E Dager
Jun 5, 2003·Expert Opinion on Pharmacotherapy·William E Dager, Richard H White
Jul 8, 2003·Clinical Pharmacokinetics·Ulf G ErikssonBengt I Eriksson
Jul 8, 2003·European Journal of Clinical Pharmacology·Gunnar FagerUlf G Eriksson
Jul 9, 2003·Clinical Pharmacokinetics·Ulf G ErikssonOla Samuelsson
Jul 9, 2003·Clinical Pharmacokinetics·Karin WåhlanderUlf G Eriksson
Citations
Sep 24, 2011·International Journal of Inflammation·Arthur J Chu
Jul 4, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Evangelia LiakoniStephan Krähenbühl
Nov 26, 2008·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Alejandro Lazo-LangnerPhilip S Wells
Feb 24, 2005·Journal of Cardiovascular Pharmacology·Spyros KokolisJonathan D Marmur
Jul 7, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael P Gulseth
Jun 11, 2005·Journal of Thrombosis and Haemostasis : JTH·Y Laurian
Aug 4, 2005·Expert Review of Cardiovascular Therapy·Christopher J Boos, Gregory Y H Lip
Oct 28, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Fabio AngeliGianpaolo Reboldi